Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR1701 + CAPOX + SHR2554 or Apatinib in Advanced Gastric Cancer
NCT07294664Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa, zeprumetostat, Rivoceranib in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by The First Affiliated Hospital of Zhengzhou University. Started Jun 2025; status: recruiting.
02
Drugs
retlirafusp alfazeprumetostatRivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07294664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07294664.